Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (560)	12/21/2001 4:08:27 PM
From: tuck	Read Replies (1) \| Respond to of 1005

We got a little spike in NWBT at the end of the day, but no news. Not worried. Meanwhile, back at the gene therapy ranch . . . >>GAITHERSBURG, Md., Dec. 21 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC - news) announced today the completion of a private placement of 3,582,000 shares of common stock that raised gross proceeds of approximately $13 million. The shares were purchased by funds managed by HealthCare Ventures. ``We are pleased with this new financial commitment and the expanded flexibility it provides our company to continue our current development programs and to explore the development of additional product candidates,'' said Paul H. Fischer, GenVec's Chief Executive Officer. The proceeds from the placement will be used to further GenVec's clinical development programs for TNFerade(TM), which is being developed for use in the treatment of certain cancers, and AdPEDF, which is being developed for use in the treatment of certain kinds of blindness, particularly macular degeneration and diabetic retinopathy, and for general corporate purposes. HealthCare Ventures based in Princeton, New Jersey, is exclusively devoted to capital formation for the healthcare industry. HealthCare Ventures (HCV) is among the largest venture capital funds in the world specialized in healthcare. HCV has formed many leading healthcare companies including MedImmune and Human Genome Sciences.<< snip Cheers, Tuck